RxDoctor Payments DataLook up a doctor →

Brock Liden

Primary Podiatric Medicine · Circleville, OHNPI 1598762692

Payments from drug & device makers

$490,269in general payments, 2019–2025

Across 483 payments — averaging $1015.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bone Support Inc.$152K
  • Kerecis Limited$138K
  • Polymedics Innovations Inc.$62K
  • Orpyx Medical Technologies Inc.$43K
  • Biotissue Holdings Inc.$31K
  • Vilex LLC$27K
  • plus $38K from 41 others
$67,525in research payments, 2019–2025

Across 9 payments — averaging $7502.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Orpyx Medical Technologies Inc.$42K
  • BONE Support AB$26K

What the payments were for

  • Royalty or licence$5,3851%
  • Consulting fees$375,65483%
  • Speaking & faculty fees$17,9454%
  • Travel & lodging$40,1189%
  • Food & beverage$12,7073%
  • Education$1,0720%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few primary podiatric medicine providers in Ohioto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$125,492
Medicare patients
173
Services billed
911

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban12$6,543
Duloxetine Hcl53$1,089
Terbinafine Hcl78$763
Doxycycline Hyclate72$545
Levetiracetam ErLevetiracetam18$405
Ciprofloxacin Hcl44$384
Gabapentin50$337
Levetiracetam18$264
Oxycodone Hcl32$221
CiclopiroxCiclopirox Olamine20$219
Triamcinolone Acetonide14$156
Metolazone13$49
Prednisone21$35
Furosemide23$28

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$318$6,54312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few primary podiatric medicine providers in Ohioon file to place this against a meaningful peer group, so we don't.

Other primary podiatric medicine in Circleville

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →